WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2002030446) REDUCTION OR PREVENTION OF POST-SURGICAL ADHESION FORMATION WITH FIBRINOGEN
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2002/030446    International Application No.:    PCT/US2001/032044
Publication Date: 18.04.2002 International Filing Date: 12.10.2001
Chapter 2 Demand Filed:    10.05.2002    
IPC:
A61K 38/36 (2006.01)
Applicants: BAXTER INTERNATIONAL INC. [US/US]; One Baxter Parkway, Deerfield, IL 60615 (US) (For All Designated States Except US).
BAXTER HEALTHCARE S.A. [CH/CH]; Hertistrasse 2, CH-8306 Wallisellen (CH) (For All Designated States Except US).
REDL, Heinz [AT/AT]; (AT) (For US Only).
SPAETHE, Reiner [DE/DE]; (DE) (For US Only).
SIMUNEK, Manuela [AT/AT]; (AT) (For US Only)
Inventors: REDL, Heinz; (AT).
SPAETHE, Reiner; (DE).
SIMUNEK, Manuela; (AT)
Agent: GUTHRIE, Janice; Baxter Healthcare Corporation, P.O. Box 15210, Irvine, CA 92623-5210 (US)
Priority Data:
60/240,200 13.10.2000 US
Title (EN) REDUCTION OR PREVENTION OF POST-SURGICAL ADHESION FORMATION WITH FIBRINOGEN
(FR) PROCEDE VISANT A REDUIRE OU A PREVENIR LA FORMATION D'ADHERENCES POST-CHIRURGICALES
Abstract: front page image
(EN)Reducing or preventing adhesions which would form in a patient during or after surgery by administering to the wound surface of a patient a fibrinogen solution in an amount of about 0.025 ml fibrinogen/cm?2¿ to about 0.25 ml fibrinogen/cm?2¿ of the surface being at risk for developing adhesions. User of fibrinogen in a preparation comprising fibrinogen at a concentration of 20 to 80 mg/ml for the reduction or prevention of post-surgical adhesion formation.
(FR)L'invention concerne un procédé visant à réduire ou à prévenir chez un patient la formation d'adhérences pendant ou après une intervention chirurgicale, qui consiste à administrer à la surface de la plaie une solution de fibrinogène à raison d'environ 0,025-0,25 ml fibrinogène/cm?2¿ de la surface présentant un risque de former des adhérences ; l'utilisation de fibrinogène dans une préparation renfermant du fibrinogène selon une concentration comprise entre 20 et 80 mg/ml, destinée à réduire ou à prévenir la formation d'adhérences post-chirurgicales.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)